Last $1.45 USD
Change Today +0.01 / 0.69%
Volume 220.4K
VTUS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

ventrus biosciences inc (VTUS) Snapshot

Open
$1.44
Previous Close
$1.44
Day High
$1.46
Day Low
$1.39
52 Week High
02/11/14 - $4.69
52 Week Low
05/19/14 - $0.85
Market Cap
33.9M
Average Volume 10 Days
297.0K
EPS TTM
$-0.96
Shares Outstanding
23.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VENTRUS BIOSCIENCES INC (VTUS)

Related News

No related news articles were found.

ventrus biosciences inc (VTUS) Related Businessweek News

No Related Businessweek News Found

ventrus biosciences inc (VTUS) Details

Ventrus Biosciences, Inc., a development-stage specialty pharmaceutical company, focuses on the late-stage development and commercialization of gastrointestinal products in the United States. The company is developing two late-stage development product candidates, including VEN 307, a diltiazem cream for the relief of pain associated with anal fissures; and VEN 308, a phenylephrine gel for the treatment of fecal incontinence associated with ileal pouch anal anastomosis. It is also involved in the development of VEN 310 as a colonic delivery mechanism, which is a PH sensitive system to deliver bacteria, complex proteins, viral antigens, small molecules, and other treatments. The company was formerly known as South Island Biosciences, Inc. and changed its name to Ventrus Biosciences, Inc. in April 2007. Ventrus BioSciences, Inc. was founded in 2005 and is headquartered in New York, New York.

10 Employees
Last Reported Date: 03/31/14
Founded in 2005

ventrus biosciences inc (VTUS) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $375.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2013.

ventrus biosciences inc (VTUS) Key Developments

Ventrus Biosciences Inc., Annual General Meeting, Jul 10, 2014

Ventrus Biosciences Inc., Annual General Meeting, Jul 10, 2014., at 10:00 US Eastern Standard Time. Location: 99 Hudson Street, 5 th Floor. Agenda: To approve the issuance of 20,322,760 shares of common stock and options to purchase 2,829,740 shares of common stock in connection with the acquisition of Assembly Pharmaceuticals, Inc.; to approve an amendment to Amended and Restated Certificate of Incorporation to effect a reverse stock split of issued and outstanding common stock at a ratio of one-for-five (1:5) and to change the name of company to "Assembly Biosciences, Inc."; to elect seven directors to serve for one-year terms expiring in 2015; to approve 2014 Stock Incentive Plan; to ratify the appointment of EisnerAmper LLP as independent registered public accounting firm for the fiscal year ending December 31, 2014; and to act upon such other matters that may properly come before the meeting or any adjournment thereof.

Ventrus Biosciences Inc. Announces Results from Second Pivotal Phase 3 Trial of Diltiazem Cream (Ven 307) in Patients with Anal Fissure

Ventrus Biosciences Inc. announced top line efficacy and safety results from the second Phase 3 clinical trial of Diltiazem Hydrochloride 2% Cream (VEN 307) in patients with pain related to anal fissure (AF). In this randomized double blind trial comparing diltiazem 2% cream versus placebo cream in 434 subjects in 90 centers globally, both treatment arms demonstrated a clinically meaningful improvement. The diltiazem 2% treatment arm demonstrated no significant improvement compared to placebo in the primary endpoint of average of worst anal pain associated with or following defecation. The mean of worst AF-related pain score at baseline was 7.09 for diltiazem 2% and 7.18 for placebo, decreasing to 3.81 (-3.28 difference) and 3.72 (-3.46 difference) respectively. Outcomes for the secondary endpoints of overall AF-related pain and PGI-I parallel the primary endpoint. Age, gender, and race were equivalent between arms, and results were not meaningfully different between countries. Adverse events (AEs) were similar for the two treatment arms. Gastrointestinal disorders were the most common with 20.7% of patients in the diltiazem 2% arm versus 21.9% in the placebo arm, substantially less than reported in the first Phase 3 trial. Reports of headaches were 5.1% for diltiazem 2% and 1.9% for placebo. There was one serious adverse event of pregnancy. In the first pivotal Phase 3 trial, the diltiazem 2% treatment arm demonstrated a statistically significant improvement compared to placebo in the primary endpoint of average of worst anal pain associated with or following defecation. The mean of worst AF-related pain score at baseline was 6.21 for diltiazem 2% and 6.38 for placebo, decreasing to 3.88 (-2.33 difference) and 4.35 (-2.03 difference) respectively (means not adjusted for baseline score).

Ventrus Biosciences Inc. Completes Enrollment of Second Pivotal Phase 3 Trial

Ventrus Biosciences Inc. announced that it has completed patient enrollment and randomization in the second Phase 3 clinical trial of Diltiazem Hydrochloride 2% Cream (VEN 307) in patients with pain related to anal fissure. Ventrus anticipates that data from this Phase 3 study will be available in the first quarter of 2014, and it expects to file a New Drug Application (NDA) for VEN 307 in the second quarter of 2014. The second pivotal Phase 3 trial, a randomized, double-blind, placebo-controlled, parallel-treatment group, multicenter efficacy and safety study of VEN 307 in subjects with AF, enrolled 434 subjects and is being conducted at 90 global clinical sites, with the majority of sites and patients located in the United States. Enrollment into this trial began in October 2012. The study's primary objective is to evaluate the efficacy of VEN 307 on reduction of worst AF-related pain associated with or following defecation when administered three times a day (TID) for 28 days. The secondary objectives are to evaluate the effect of VEN 307 on reduction of overall daily AF-related pain and to evaluate patient global impression of improvement (PGI-I) at Day 29 in subjects with AF-related pain. To be eligible for randomization into the study, all patients had to have sufficient baseline AF-related pain associated with or following defecation of >= 5 on an 11-point numerical rating score (NRS) scale with 0 being no pain and 10 being the worst possible pain.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VTUS:US $1.45 USD +0.01

VTUS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VTUS.
View Industry Companies
 

Industry Analysis

VTUS

Industry Average

Valuation VTUS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VENTRUS BIOSCIENCES INC, please visit www.ventrusbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.